Breakthrough eyedrop therapeutic to treat Diabetic Retinopathy.
Oklahoma City, OK and Seattle, WA (PRWEB) May 04, 2015 — EyeCRO LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation platform developed by EyeCRO, which can deliver drugs to the front and back of the eye via a topical eyedrop.
Under the terms of the agreement, EyeCRO will receive a tiered single-digit royalty on commercialized products for ophthalmologic indications as well as a number of development and regulatory milestones. In exchange, NeuMedics will receive a license for exclusive rights to formulate their class of molecules utilizing the MiDROPS™ platform.
“We look forward to developing this partnership with NeuMedics to further advance our MiDROPS™ platform into clinical trials”, said Rafal Farjo, Ph.D., Chief Operating Officer of EyeCRO. Read the entire news release here.
